The FDA approved pegcetacoplan (EMPAVELI; Apellis Pharmaceuticals) as the first treatment for patients aged 12 and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...

Dozens of lawmakers are urging U.S. health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

An unusual FDA panel on antidepressant use during pregnancy elevated clinicians and researchers who are deeply skeptical of ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

One study (gabapentin 900 mg/day versus amitriptyline 10 mg/day, 34 participants, for 6 weeks) did not report our primary outcomes. The second study (pregabalin 75 to 450 mg/day versus placebo 75 to ...

All patients received and maintained a dose of 75 mg pregabalin twice daily for analgesia during the treatment period (7 days), and then patients stopped stimulation and entered a 16-week follow-up ...

The final, formatted version of the article will be published soon. Pregabalin (PGL) is a medication that is prescribed for controlling specific neurological-related symptoms. Due to its abuse in ...

This review updates part of an earlier Cochrane review on 'Pregabalin for acute and chronic pain in adults' (Moore 2009), and considers only fibromyalgia pain. Antiepileptic drugs have been used in ...

Pregabalin-only overdose generally causes mild symptoms, although seizures and coma have been rarely reported (3). The incidence of severe pregabalin poisoning with coma and signs of encephalopathy is ...